Skip to content
2000
image of Genomic Medicine: A Critical Review of its Impact on Diagnosing and Treating Genetic Disorders

Abstract

Genomic medicine is revolutionizing genetic disease diagnosis and therapy; has a major impact on clinical practice, particularly in diagnosis and treatment. In addition, next-generation sequencing (NGS) has transformed diagnostics. These advances have made genome profiling cost-effective and fast, helping us find pathogenic variations that cause a variety of genetic illnesses. Given its influence on diagnostic methods, NGS mutation detection accuracy and reliability must be assessed. In therapeutics, genomic medicine has introduced precision methods. CRISPR-Cas9 gene editing, and new RNA-based therapies are being evaluated for the treatment of genetic mutations Pharmacogenomics' capacity to customize medication regimens to genetic profiles, optimizing therapeutic results while minimizing side effects, is also evaluated. Although genetic medicine has transformational promise, its widespread acceptance is difficult. Obtaining widespread acceptance of genetic medicine is difficult because of worries around ethical implications, privacy problems, and the possibility for genetic information to be misused. Ethics and privacy issues surrounding genetic information usage require considerable thought. Genomic data integration into clinical practice requires robust regulatory frameworks. The influence of NGS technology and precision treatments on genetic disease diagnosis and therapy is significant. This review emphasizes the importance of assessing diagnostic tools, comprehending novel therapy modalities, and addressing ethical and regulatory issues to enable responsible and successful clinical integration.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cgt/10.2174/0115665232389198250711180547
2025-07-22
2025-10-29

  • From This Site

    /content/journals/cgt/10.2174/0115665232389198250711180547
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Meng K. Johnson T.F. Alvarez-Fernandez A. Guldin S. Bracewell D.G. Opportunities for isoporous membranes in the manufacture of genomic medicines. J Membr Sci Lett 2023 3 2 100052 10.1016/j.memlet.2023.100052
    [Google Scholar]
  2. Cecchi A.C. Drake M. Campos C. Current state and future directions of genomic medicine in aortic dissection: A path to prevention and personalized care. Semin. Vasc. Surg. 2022 35 1 51 59 10.1053/j.semvascsurg.2022.02.003 35501041
    [Google Scholar]
  3. Kingsmore S.F. Smith L.D. Kunard C.M. A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases. Am. J. Hum. Genet. 2022 109 9 1605 1619 10.1016/j.ajhg.2022.08.003 36007526
    [Google Scholar]
  4. Miller S. Chiu C. The role of metagenomics and next-generation sequencing in infectious disease diagnosis. Clin. Chem. 2021 68 1 115 124 10.1093/clinchem/hvab173 34969106
    [Google Scholar]
  5. Paramasivam G. Sanmugam A. Palem V.V. Nanomaterials for detection of biomolecules and delivering therapeutic agents in theragnosis: A review. Int. J. Biol. Macromol. 2024 254 Pt 2 127904 10.1016/j.ijbiomac.2023.127904 37939770
    [Google Scholar]
  6. Satam H. Joshi K. Mangrolia U. Next-generation sequencing technology: Current trends and advancements. Biology 2023 12 7 997 10.3390/biology12070997 37508427
    [Google Scholar]
  7. Jaffe E.S. Evolution of lymphoma diagnosis in the era of personalized medicine. Am. J. Pathol. 2023 193 12 1880 1886 10.1016/j.ajpath.2023.08.012 37734589
    [Google Scholar]
  8. Khoury M.J. Bowen S. Dotson W.D. Health equity in the implementation of genomics and precision medicine: A public health imperative. Genet. Med. 2022 24 8 1630 1639 10.1016/j.gim.2022.04.009 35482015
    [Google Scholar]
  9. Lupski J.R. Biology in balance: Human diploid genome integrity, gene dosage, and genomic medicine. Trends Genet. 2022 38 6 554 571 10.1016/j.tig.2022.03.001 35450748
    [Google Scholar]
  10. Jimenez J.E. Nourbakhsh A. Colbert B. Diagnostic and therapeutic applications of genomic medicine in progressive, late-onset, nonsyndromic sensorineural hearing loss. Gene 2020 747 144677 10.1016/j.gene.2020.144677 32304785
    [Google Scholar]
  11. Pearce C. Goettke E. Hallowell N. McCormack P. Flinter F. McKevitt C. Delivering genomic medicine in the United Kingdom National Health Service: A systematic review and narrative synthesis. Genet. Med. 2019 21 12 2667 2675 10.1038/s41436‑019‑0579‑x 31186523
    [Google Scholar]
  12. Stenzinger A. Edsjö A. Ploeger C. Trailblazing precision medicine in Europe: A joint view by genomic medicine sweden and the centers for personalized medicine, ZPM, in Germany. Semin. Cancer Biol. 2022 84 242 254 10.1016/j.semcancer.2021.05.026 34033893
    [Google Scholar]
  13. Sidiropoulos N. Operationalizing genomic medicine. Adv Mol Pathol 2021 4 173 185 10.1016/j.yamp.2021.07.006
    [Google Scholar]
  14. Hastings R. Dixit A. Genomic medicine for the paediatrician. Paediatr. Child Health 2019 29 4 185 189 10.1016/j.paed.2019.01.015
    [Google Scholar]
  15. Arcila M.E. Snow A.N. Akkari Y.M.N. Chabot-Richards D. Pancholi P. Tafe L.J. Molecular pathology education: A suggested framework for primary care resident training in genomic medicine. J. Mol. Diagn. 2022 24 5 430 441 10.1016/j.jmoldx.2021.12.013 35304347
    [Google Scholar]
  16. Wise A.L. Manolio T.A. Mensah G.A. Genomic medicine for undiagnosed diseases. Lancet 2019 394 10197 533 540 10.1016/S0140‑6736(19)31274‑7 31395441
    [Google Scholar]
  17. Yue R. Dutta A. Computational systems biology in disease modeling and control, review and perspectives. NPJ Syst. Biol. Appl. 2022 8 1 37 10.1038/s41540‑022‑00247‑4 36192551
    [Google Scholar]
  18. Marques L. Costa B. Pereira M. Advancing precision medicine: A review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics 2024 16 3 332 10.3390/pharmaceutics16030332 38543226
    [Google Scholar]
  19. Hussen B.M. Abdullah S.T. Salihi A. The emerging roles of NGS in clinical oncology and personalized medicine. Pathol. Res. Pract. 2022 230 153760 10.1016/j.prp.2022.153760 35033746
    [Google Scholar]
  20. Bidzimou M.T.K. Landstrom A.P. From diagnostic testing to precision medicine: The evolving role of genomics in cardiac channelopathies and cardiomyopathies in children. Curr. Opin. Genet. Dev. 2022 76 101978 10.1016/j.gde.2022.101978 36058060
    [Google Scholar]
  21. Yao Q. Gorevic P. Shen B. Gibson G. Genetically transitional disease: A new concept in genomic medicine. Trends Genet. 2023 39 2 98 108 10.1016/j.tig.2022.11.002 36564319
    [Google Scholar]
  22. Manolio T.A. Implementing genomics and pharmacogenomics in the clinic: The national human genome research institute’s genomic medicine portfolio. Atherosclerosis 2016 253 225 236 10.1016/j.atherosclerosis.2016.08.034 27612677
    [Google Scholar]
  23. Pyeritz R.E. Uncertainty in genomics impacts precision medicine. Trends Genet. 2021 37 8 711 716 10.1016/j.tig.2020.10.010 33218792
    [Google Scholar]
  24. Heydt C Kostenko A Merkelbach-Bruse S Wolf J Büttner R. ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): The Cologne model for implementing personalised oncology. Ann Oncol 2016 27 iii25 34.(Suppl. 3) 10.1093/annonc/mdw303 27573753
    [Google Scholar]
  25. MacLeod J.N. Kalbfleisch T.S. Genetics, genomics, and emergent precision medicine 12 years after the equine reference genome was published. Vet. Clin. North Am. Equine Pract. 2020 36 2 173 181 10.1016/j.cveq.2020.04.002 32654780
    [Google Scholar]
  26. Wong S.X.E. Kiew S.F. Lau S.Y. Pottas P.W. Procedures to investigate potential of plants as natural food preservatives: Extraction technology, phytochemical characterisation, and antimicrobial bioassays. Food Chem Adv 2023 3 100435 10.1016/j.focha.2023.100435
    [Google Scholar]
  27. Peterson J.F. Roden D.M. Orlando L.A. Ramirez A.H. Mensah G.A. Williams M.S. Building evidence and measuring clinical outcomes for genomic medicine. Lancet 2019 394 10198 604 610 10.1016/S0140‑6736(19)31278‑4 31395443
    [Google Scholar]
  28. Zhang Y. Karakikes I. Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9. Trends Cardiovasc. Med. 2021 31 6 341 348 10.1016/j.tcm.2020.06.008 32603681
    [Google Scholar]
  29. Bierut L.J. Tyndale R.F. Preparing the way: Exploiting genomic medicine to stop smoking. Trends Mol. Med. 2018 24 2 187 196 10.1016/j.molmed.2017.12.001 29307500
    [Google Scholar]
  30. Tran T.H. Hunger S.P. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. Semin. Cancer Biol. 2022 84 144 152 10.1016/j.semcancer.2020.10.013 33197607
    [Google Scholar]
  31. Yaspo M.L. Taking a functional genomics approach in molecular medicine. Trends Mol. Med. 2001 7 11 494 501 10.1016/S1471‑4914(01)02181‑5 11689334
    [Google Scholar]
  32. Clark A.J. Lillard J.W. A comprehensive review of bioinformatics tools for genomic biomarker discovery driving precision oncology. Genes 2024 15 8 1036 10.3390/genes15081036 39202397
    [Google Scholar]
  33. Abdi G. Jain M. Barwant M. Unveiling the dynamic role of bioinformatics in automation for efficient and accurate data processing and interpretation. Advances in Bioinformatics. Singapore Springer Nature Singapore 2024 279 319 10.1007/978‑981‑99‑8401‑5_15
    [Google Scholar]
  34. Dotolo S. Esposito Abate R. Roma C. Bioinformatics: From NGS data to biological complexity in variant detection and oncological clinical practice. Biomedicines 2022 10 9 2074 10.3390/biomedicines10092074 36140175
    [Google Scholar]
  35. Zech M. Winkelmann J. Next-generation sequencing and bioinformatics in rare movement disorders. Nat. Rev. Neurol. 2024 20 2 114 126 10.1038/s41582‑023‑00909‑9 38172289
    [Google Scholar]
  36. Krishnan R.P. Pandiar D. Ramani P. Jayaraman S. Molecular profiling of oral epithelial dysplasia and oral squamous cell carcinoma using next generation sequencing. J. Stomatol. Oral Maxillofac. Surg. 2025 126 4 102120 10.1016/j.jormas.2024.102120 39424062
    [Google Scholar]
  37. Hartmann K. Sadée C.Y. Satwah I. Carrillo-Perez F. Gevaert O. Imaging genomics: Data fusion in uncovering disease heritability. Trends Mol. Med. 2023 29 2 141 151 10.1016/j.molmed.2022.11.002 36470817
    [Google Scholar]
  38. Mekbib K.Y. Muñoz W. Allington G. Human genetics and molecular genomics of Chiari malformation type 1. Trends Mol. Med. 2023 29 12 1059 1075 10.1016/j.molmed.2023.08.013 37802664
    [Google Scholar]
  39. Mould A.W. Hall N.A. Milosevic I. Tunbridge E.M. Targeting synaptic plasticity in schizophrenia: Insights from genomic studies. Trends Mol. Med. 2021 27 11 1022 1032 10.1016/j.molmed.2021.07.014 34419330
    [Google Scholar]
  40. Shen S. Sun Y. Matsumoto M. Integrating single-cell genomics pipelines to discover mechanisms of stem cell differentiation. Trends Mol. Med. 2021 27 12 1135 1158 10.1016/j.molmed.2021.09.006 34657800
    [Google Scholar]
  41. Duijf P.H.G. Nanayakkara D. Nones K. Srihari S. Kalimutho M. Khanna K.K. Mechanisms of genomic instability in breast cancer. Trends Mol. Med. 2019 25 7 595 611 10.1016/j.molmed.2019.04.004 31078431
    [Google Scholar]
  42. Rivera-Reyes A. Hayer K.E. Bassing C.H. Genomic alterations of non-coding regions underlie human cancer: Lessons from T-ALL. Trends Mol. Med. 2016 22 12 1035 1046 10.1016/j.molmed.2016.10.004 28240214
    [Google Scholar]
  43. Bauer D.C. Gaff C. Dinger M.E. Genomics and personalised whole-of-life healthcare. Trends Mol. Med. 2014 20 9 479 486 10.1016/j.molmed.2014.04.001 24801560
    [Google Scholar]
  44. Wong A.I.C. Lo Y.M.D. Noninvasive fetal genomic, methylomic, and transcriptomic analyses using maternal plasma and clinical implications. Trends Mol. Med. 2015 21 2 98 108 10.1016/j.molmed.2014.12.006 25618775
    [Google Scholar]
  45. Gingold J.A. Zhu D. Lee D.F. Kaseb A. Chen J. Genomic profiling and metabolic homeostasis in primary liver cancers. Trends Mol. Med. 2018 24 4 395 411 10.1016/j.molmed.2018.02.006 29530485
    [Google Scholar]
  46. Burke W. Parens E. Chung W.K. Berger S.M. Appelbaum P.S. The challenge of genetic variants of uncertain clinical significance: A narrative review. Ann. Intern. Med. 2022 175 7 994 1000 10.7326/M21‑4109 35436152
    [Google Scholar]
  47. Spielmann M. Kircher M. Computational and experimental methods for classifying variants of unknown clinical significance. Cold Spring Harb. Mol. Case Stud. 2022 8 3 a006196 10.1101/mcs.a006196 35483875
    [Google Scholar]
  48. Mocellin S. Riccardo Rossi C. Traldi P. Nitti D. Lise M. Molecular oncology in the post-genomic era: The challenge of proteomics. Trends Mol. Med. 2004 10 1 24 32 10.1016/j.molmed.2003.11.001 14720583
    [Google Scholar]
  49. Pulighe G. Pirelli T. Assessing the sustainability of bioenergy pathways through a land-water-energy nexus approach. Renew. Sustain. Energy Rev. 2023 184 113539 10.1016/j.rser.2023.113539
    [Google Scholar]
  50. Blackwell J.M. Genetics and genomics in infectious disease susceptibility. Trends Mol. Med. 2001 7 11 521 526 10.1016/S1471‑4914(01)02169‑4 11689339
    [Google Scholar]
  51. Kong H.H. Skin microbiome: Genomics-based insights into the diversity and role of skin microbes. Trends Mol. Med. 2011 17 6 320 328 10.1016/j.molmed.2011.01.013 21376666
    [Google Scholar]
  52. Fernandes-Rosa F.L. Boulkroun S. Zennaro M.C. Genetic and genomic mechanisms of primary aldosteronism. Trends Mol. Med. 2020 26 9 819 832 10.1016/j.molmed.2020.05.005 32563556
    [Google Scholar]
  53. Lagasse E. Levin M. Future medicine: From molecular pathways to the collective intelligence of the body. Trends Mol. Med. 2023 29 9 687 710 10.1016/j.molmed.2023.06.007 37481382
    [Google Scholar]
  54. Basinski B.W. Balikov D.A. Aksu M. Li Q. Rao R.C. Ubiquitous chromatin modifiers in congenital retinal diseases: Implications for disease modeling and regenerative medicine. Trends Mol. Med. 2021 27 4 365 378 10.1016/j.molmed.2021.01.001 33573910
    [Google Scholar]
  55. Polk J.B. Campbell J. Drilon A.E. Keating P. Cambrosio A. Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center’s engagement in/with genomics. Soc. Sci. Med. 2023 324 115789 10.1016/j.socscimed.2023.115789 36996726
    [Google Scholar]
  56. Lemaitre F. Florentin V. Blin O. Can precision medicine be integrated into routine therapeutic decisions at the bedside of patients? Therapie 2024 79 1 13 22 10.1016/j.therap.2023.11.007 38065821
    [Google Scholar]
  57. Huang K. Xiao C. Glass L.M. Critchlow C.W. Gibson G. Sun J. Machine learning applications for therapeutic tasks with genomics data. Patterns 2021 2 10 100328 10.1016/j.patter.2021.100328 34693370
    [Google Scholar]
  58. Safdar M. Ullah M. Wahab A. Genomic insights into heart health: Exploring the genetic basis of cardiovascular disease. Curr. Probl. Cardiol. 2024 49 1 102182 10.1016/j.cpcardiol.2023.102182 37913933
    [Google Scholar]
  59. Wang D. Liu B. Zhang Z. Accelerating the understanding of cancer biology through the lens of genomics. Cell 2023 186 8 1755 1771 10.1016/j.cell.2023.02.015 37059071
    [Google Scholar]
  60. Ginsburg G.S. Penny M. Feero W.G. Miller M. Addie S. Beachy S.H. The national academies’ roundtable on genomics and precision health: Where we have been and where we are heading. Am. J. Hum. Genet. 2021 108 10 1817 1822 10.1016/j.ajhg.2021.08.015 34626581
    [Google Scholar]
  61. Pronyk P.M. de Alwis R. Rockett R. Advancing pathogen genomics in resource-limited settings. Cell Genomics 2023 3 12 100443 10.1016/j.xgen.2023.100443 38116115
    [Google Scholar]
  62. Smith H.S. Brothers K.B. Knight S.J. Conceptualization of utility in translational clinical genomics research. Am. J. Hum. Genet. 2021 108 11 2027 2036 10.1016/j.ajhg.2021.08.013 34687653
    [Google Scholar]
  63. Patel R.K. Rahman S. Schwantes I.R. Updated management of colorectal cancer liver metastases: Scientific advances driving modern therapeutic innovations. Cell. Mol. Gastroenterol. Hepatol. 2023 16 6 881 894 10.1016/j.jcmgh.2023.08.012 37678799
    [Google Scholar]
  64. Rizzuti M. Sali L. Melzi V. Genomic and transcriptomic advances in amyotrophic lateral sclerosis. Ageing Res. Rev. 2023 92 102126 10.1016/j.arr.2023.102126 37972860
    [Google Scholar]
  65. Chon E. Hendricks W. White M. Rodrigues L. Haworth D. Post G. Precision medicine in veterinary science. Vet. Clin. North Am. Small Anim. Pract. 2024 54 3 501 521 10.1016/j.cvsm.2023.12.006 38212188
    [Google Scholar]
  66. Biancolella M. Testa B. Salehi L.B. D’Apice M.R. Novelli G. Genetics and genomics of breast cancer: Update and translational perspectives. Semin. Cancer Biol. 2021 72 27 35 10.1016/j.semcancer.2020.03.013 32259642
    [Google Scholar]
  67. Elumalai P. Ezhilarasan D. Emerging applications of CRISPR/Cas9 gene editing technology in reversing drug resistance in oral squamous cell carcinoma. Oral Oncol. 2022 134 106100 10.1016/j.oraloncology.2022.106100 36063701
    [Google Scholar]
  68. Frangoul H. Altshuler D. Cappellini M.D. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med. 2021 384 3 252 260 10.1056/NEJMoa2031054 33283989
    [Google Scholar]
  69. Wei R. Yang J. Cheng C.W. CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson’s disease. JHEP Rep Innov Hepatol 2022 4 1 100389 10.1016/j.jhepr.2021.100389 34877514
    [Google Scholar]
  70. Alkanli S.S. Alkanli N. Ay A. Albeniz I. CRISPR/Cas9 mediated therapeutic approach in Huntington’s disease. Mol. Neurobiol. 2023 60 3 1486 1498 10.1007/s12035‑022‑03150‑5 36482283
    [Google Scholar]
  71. Song G. Ma Y. Gao X. CRISPR/Cas9-mediated genetic correction reverses spinocerebellar ataxia 3 disease-associated phenotypes in differentiated cerebellar neurons. Life Med 2022 1 1 27 44 10.1093/lifemedi/lnac020 39872157
    [Google Scholar]
  72. Abdelnour S.A. Xie L. Hassanin A.A. Zuo E. Lu Y. The potential of CRISPR/Cas9 gene editing as a treatment strategy for inherited diseases. Front. Cell Dev. Biol. 2021 9 699597 10.3389/fcell.2021.699597 34977000
    [Google Scholar]
  73. Sharma M. Pal P. Gupta S.K. The neurotransmitter puzzle of Alzheimer’s: Dissecting mechanisms and exploring therapeutic horizons. Brain Res. 2024 1829 148797 10.1016/j.brainres.2024.148797 38342422
    [Google Scholar]
  74. Hamza M. Dionne R.A. 2020 foresight: Envisioning therapeutic innovations for pain. Drug Discov. Today Ther. Strateg. 2009 6 3 113 119 10.1016/j.ddstr.2010.10.002 21712969
    [Google Scholar]
  75. Bamodu O.A. Chung C.C. Pisanic T.R. Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine. J Liq Biopsy 2023 2 100126 10.1016/j.jlb.2023.100126 40028482
    [Google Scholar]
  76. Barrera-Saldaña H.A. Origin of personalized medicine in pioneering, passionate, genomic research. Genomics 2020 112 1 721 728 10.1016/j.ygeno.2019.05.006 31078717
    [Google Scholar]
  77. Sarhangi N. Rouhollah F. Niknam N. Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population. Daru 2024 32 2 715 727 10.1007/s40199‑024‑00538‑7 39424756
    [Google Scholar]
  78. Thornley T. Esquivel B. Wright D.J. Dop H. Kirkdale C.L. Youssef E. Implementation of a pharmacogenomic testing service through community pharmacy in the Netherlands: Results from an early service evaluation. Pharmacy 2021 9 1 38 10.3390/pharmacy9010038 33673111
    [Google Scholar]
  79. Cohn I. Manshaei R. Liston E. Assessment of the implementation of pharmacogenomic testing in a pediatric tertiary care setting. JAMA Netw. Open 2021 4 5 e2110446 10.1001/jamanetworkopen.2021.10446 34037732
    [Google Scholar]
  80. Nahid N.A. Johnson J.A. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. Expert Opin. Drug Metab. Toxicol. 2022 18 11 769 785 10.1080/17425255.2022.2160317 36597259
    [Google Scholar]
  81. Brooks I.R. Garrone C.M. Kerins C. Functional genomics and the future of iPSCs in disease modeling. Stem Cell Reports 2022 17 5 1033 1047 10.1016/j.stemcr.2022.03.019 35487213
    [Google Scholar]
  82. Fulton-Ward T. Middleton G. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A comprehensive review. Ann. Oncol. 2023 34 12 1113 1130 10.1016/j.annonc.2023.10.124 37875224
    [Google Scholar]
  83. Wei Y. Erfani S. Schweer D. Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies. Mol. Ther. Oncolytics 2023 28 293 306 10.1016/j.omto.2023.02.006 36911068
    [Google Scholar]
  84. Cheng L. Newbold K. Genomic landscape of anaplastic thyroid cancer and implications on therapy. Curr. Opin. Endocr. Metab. Res. 2023 30 100458 10.1016/j.coemr.2023.100458
    [Google Scholar]
  85. Fang J. Chen Q. Wu G. Genomics-based tools for drug discovery and development: From network maps to efficacy prediction. J Holist Integr Pharm 2023 4 3 199 209 10.1016/j.jhip.2023.11.001
    [Google Scholar]
  86. Machiels M. Oulkadi R. Tramm T. Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers. Breast 2023 71 13 21 10.1016/j.breast.2023.06.010 37437386
    [Google Scholar]
  87. Ren J. Yang L. Qiu S. Zhang A.H. Wang X.J. Efficacy evaluation, active ingredients, and multitarget exploration of herbal medicine. Trends Endocrinol. Metab. 2023 34 3 146 157 10.1016/j.tem.2023.01.005 36710216
    [Google Scholar]
  88. Wang M. Su J. Lu J. Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis? Clin. Res. Hepatol. Gastroenterol. 2023 47 2 102078 10.1016/j.clinre.2023.102078 36627051
    [Google Scholar]
  89. Tilak T.V.S.V.G.K. Patel A. Kapoor A. Molecular basis and clinical application of targeted therapy in oncology. Med. J. Armed Forces India 2023 79 2 128 135 10.1016/j.mjafi.2023.02.001 36969115
    [Google Scholar]
  90. Guo S. Zhu X. Huang Z. Genomic instability drives tumorigenesis and metastasis and its implications for cancer therapy. Biomed. Pharmacother. 2023 157 114036 10.1016/j.biopha.2022.114036 36436493
    [Google Scholar]
  91. Labrie M. Brugge J.S. Mills G.B. Zervantonakis I.K. Therapy resistance: Opportunities created by adaptive responses to targeted therapies in cancer. Nat. Rev. Cancer 2022 22 6 323 339 10.1038/s41568‑022‑00454‑5 35264777
    [Google Scholar]
  92. Sivalingam A.M. Advances in understanding biomarkers and treating neurological diseases – Role of the cerebellar dysfunction and emerging therapies. Ageing Res. Rev. 2024 101 102519 10.1016/j.arr.2024.102519 39341507
    [Google Scholar]
  93. Wekking D. Pretta A. Martella S. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas. Heliyon 2023 9 9 e19541 10.1016/j.heliyon.2023.e19541 37681152
    [Google Scholar]
  94. Fujiwara Y. Kato S. Kurzrock R. Evolution of precision oncology, personalized medicine, and molecular tumor boards. Surg. Oncol. Clin. N. Am. 2023 33 2 197 216 10.1016/j.soc.2023.12.004 38401905
    [Google Scholar]
  95. Zhang Z. Wei X. Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy. Semin. Cancer Biol. 2023 90 57 72 10.1016/j.semcancer.2023.02.005 36796530
    [Google Scholar]
  96. Natri H.M. Chapman C.R. Heraty S. Ethical challenges in autism genomics: Recommendations for researchers. Eur. J. Med. Genet. 2023 66 9 104810 10.1016/j.ejmg.2023.104810 37478903
    [Google Scholar]
  97. Marron J.M. Joffe S. Ethical considerations in genomic testing for hematologic disorders. Blood 2017 130 4 460 465 10.1182/blood‑2017‑01‑734558 28600340
    [Google Scholar]
  98. Lyon G.J. Segal J.P. Practical, ethical and regulatory considerations for the evolving medical and research genomics landscape. Appl. Transl. Genomics 2013 2 34 40 10.1016/j.atg.2013.02.001 27942444
    [Google Scholar]
  99. Sen S.K. Green E.D. Hutter C.M. Craven M. Ideker T. Di Francesco V. Opportunities for basic, clinical, and bioethics research at the intersection of machine learning and genomics. Cell Genomics 2024 4 1 100466 10.1016/j.xgen.2023.100466 38190108
    [Google Scholar]
  100. Bankoff R.J. Perry G.H. Hunter–gatherer genomics: Evolutionary insights and ethical considerations. Curr. Opin. Genet. Dev. 2016 41 1 7 10.1016/j.gde.2016.06.015 27400119
    [Google Scholar]
  101. Richardson A. Ormond K.E. Ethical considerations in prenatal testing: Genomic testing and medical uncertainty. Semin. Fetal Neonatal Med. 2018 23 1 1 6 10.1016/j.siny.2017.10.001 29033309
    [Google Scholar]
  102. Clayton E.W. Smith M.E. Anderson K.C. Studying the impact of translational genomic research: Lessons from eMERGE. Am. J. Hum. Genet. 2023 110 7 1021 1033 10.1016/j.ajhg.2023.05.011 37343562
    [Google Scholar]
  103. Fusar-Poli P. Manchia M. Koutsouleris N. Ethical considerations for precision psychiatry: A roadmap for research and clinical practice. Eur. Neuropsychopharmacol. 2022 63 17 34 10.1016/j.euroneuro.2022.08.001 36041245
    [Google Scholar]
  104. Hammer M.J. Beyond the helix: Ethical, legal, and social implications in genomics. Semin. Oncol. Nurs. 2019 35 1 93 106 10.1016/j.soncn.2018.12.007 30683550
    [Google Scholar]
  105. Bolleddula J. Simeon D. Anderson S.G. No person left behind: Mapping the health policy landscape for genomics research in the Caribbean. Lancet Reg Health Am 2022 15 100367 10.1016/j.lana.2022.100367 36778076
    [Google Scholar]
  106. Umbach N. Beißbarth T. Bleckmann A. Clinical application of genomic high-throughput data: Infrastructural, ethical, legal and psychosocial aspects. Eur. Neuropsychopharmacol. 2020 31 1 15 10.1016/j.euroneuro.2019.09.008 31866110
    [Google Scholar]
  107. Hazin R. Brothers K.B. Malin B.A. Ethical, legal, and social implications of incorporating genomic information into electronic health records. Genet. Med. 2013 15 10 810 816 10.1038/gim.2013.117 24030434
    [Google Scholar]
  108. Ellard H. Alfardus H. Sanderson S. Lewis C. What does a consent conversation for whole genome sequencing look like in the NHS Genomic Medicine Service? An observational study. Eur. J. Hum. Genet. 2025 33 4 504 512 10.1038/s41431‑024‑01749‑x 39592828
    [Google Scholar]
  109. Huang S.J. Amendola L.M. Sternen D.L. Variation among DNA banking consent forms: Points for clinicians to bank on. J. Community Genet. 2022 13 4 389 397 10.1007/s12687‑022‑00601‑3 35834113
    [Google Scholar]
  110. Kurant D.E. Opportunities and challenges with artificial intelligence in genomics. Clin. Lab. Med. 2023 43 1 87 97 10.1016/j.cll.2022.09.007 36764810
    [Google Scholar]
  111. Lemke A.A. Esplin E.D. Goldenberg A.J. Addressing underrepresentation in genomics research through community engagement. Am. J. Hum. Genet. 2022 109 9 1563 1571 10.1016/j.ajhg.2022.08.005 36055208
    [Google Scholar]
  112. Teare H.J.A. Prictor M. Kaye J. Reflections on dynamic consent in biomedical research: The story so far. Eur. J. Hum. Genet. 2021 29 4 649 656 10.1038/s41431‑020‑00771‑z 33249421
    [Google Scholar]
  113. Bedrosian I. Somerfield M.R. Achatz M.I. Germline testing in patients with breast cancer: ASCO–Society of Surgical Oncology guideline. J. Clin. Oncol. 2024 42 5 584 604 10.1200/JCO.23.02225 38175972
    [Google Scholar]
  114. Skantharajah N. Baichoo S. Boughtwood T.F. Equity, diversity, and inclusion at the Global Alliance for Genomics and Health. Cell Genomics 2023 3 10 100386 10.1016/j.xgen.2023.100386 37868041
    [Google Scholar]
  115. Hiratsuka V.Y. Hahn M.J. Woodbury R.B. Alaska Native genomic research: Perspectives from Alaska Native leaders, federal staff, and biomedical researchers. Genet. Med. 2020 22 12 1935 1943 10.1038/s41436‑020‑0926‑y 32839571
    [Google Scholar]
  116. Vitti J.J. Cho M.K. Tishkoff S.A. Sabeti P.C. Human evolutionary genomics: Ethical and interpretive issues. Trends Genet. 2012 28 3 137 145 10.1016/j.tig.2011.12.001 22265990
    [Google Scholar]
  117. Stark Z. Boughtwood T. Haas M. Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare. Am. J. Hum. Genet. 2023 110 3 419 426 10.1016/j.ajhg.2023.01.018 36868206
    [Google Scholar]
  118. Baker K.S. Jauneikaite E. Hopkins K.L. Genomics for public health and international surveillance of antimicrobial resistance. Lancet Microbe 2023 4 12 e1047 e1055 10.1016/S2666‑5247(23)00283‑5 37977162
    [Google Scholar]
  119. Bombard Y. Ginsburg G.S. Sturm A.C. Zhou A.Y. Lemke A.A. Digital health-enabled genomics: Opportunities and challenges. Am. J. Hum. Genet. 2022 109 7 1190 1198 10.1016/j.ajhg.2022.05.001 35803232
    [Google Scholar]
  120. Wheeler N.E. Price V. Cunningham-Oakes E. Innovations in genomic antimicrobial resistance surveillance. Lancet Microbe 2023 4 12 e1063 e1070 10.1016/S2666‑5247(23)00285‑9 37977163
    [Google Scholar]
  121. Sathishkumar K. Sudhakaran G. Moovendhan M. Haridevamuthu B. AI and genomics: Navigating the future of personalized medicine and ethical challenges. Oral Oncology Reports 2024 10 100419 10.1016/j.oor.2024.100419
    [Google Scholar]
  122. Zhang C. Hansen M.E.B. Tishkoff S.A. Advances in integrative African genomics. Trends Genet. 2022 38 2 152 168 10.1016/j.tig.2021.09.013 34740451
    [Google Scholar]
  123. Rehm H.L. Page A.J.H. Smith L. GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics 2021 1 2 100029 10.1016/j.xgen.2021.100029 35072136
    [Google Scholar]
  124. Robertson A.J. Tan N.B. Spurdle A.B. Metke-Jimenez A. Sullivan C. Waddell N. Re-analysis of genomic data: An overview of the mechanisms and complexities of clinical adoption. Genet. Med. 2022 24 4 798 810 10.1016/j.gim.2021.12.011 35065883
    [Google Scholar]
  125. Inzaule S.C. Tessema S.K. Kebede Y. Ogwell Ouma A.E. Nkengasong J.N. Genomic-informed pathogen surveillance in Africa: Opportunities and challenges. Lancet Infect. Dis. 2021 21 9 e281 e289 10.1016/S1473‑3099(20)30939‑7 33587898
    [Google Scholar]
  126. Hassoun A. Garcia-Garcia G. Trollman H. Birth of dairy 4.0: Opportunities and challenges in adoption of fourth industrial revolution technologies in the production of milk and its derivatives. Curr Res Food Sci 2023 7 100535 10.1016/j.crfs.2023.100535 37448632
    [Google Scholar]
  127. Gropman A.L. Uittenbogaard M.N. Chiaramello A.E. Challenges and opportunities to bridge translational to clinical research for personalized mitochondrial medicine. Neurotherapeutics 2024 21 1 e00311 10.1016/j.neurot.2023.e00311 38266483
    [Google Scholar]
  128. Jones H.E. Wilson P.B. Progress and opportunities through use of genomics in animal production. Trends Genet. 2022 38 12 1228 1252 10.1016/j.tig.2022.06.014 35945076
    [Google Scholar]
  129. Hasan L. Misra A. Molecular diagnostics for invasive fungal infections: Barriers to widespread adoption and opportunities for improvement. Advances in Molecular Pathology 2023 6 1 51 68 10.1016/j.yamp.2023.08.003
    [Google Scholar]
  130. Furstenau L.B. Leivas P. Sott M.K. Big data in healthcare: Conceptual network structure, key challenges and opportunities. Digit Commun Netw 2023 9 4 856 868 10.1016/j.dcan.2023.03.005
    [Google Scholar]
  131. Rupp B. Ball H. Wuchu F. Nagrath D. Nagrath S. Circulating tumor cells in precision medicine: Challenges and opportunities. Trends Pharmacol. Sci. 2022 43 5 378 391 10.1016/j.tips.2022.02.005 35272862
    [Google Scholar]
  132. Guan Z. Li H. Liu R. Artificial intelligence in diabetes management: Advancements, opportunities, and challenges. Cell Rep. Med. 2023 4 10 101213 10.1016/j.xcrm.2023.101213 37788667
    [Google Scholar]
  133. Alvarez-Gomez R.M. De la Fuente-Hernandez M.A. Herrera-Montalvo L. Hidalgo-Miranda A. Challenges of diagnostic genomics in Latin America. Curr. Opin. Genet. Dev. 2021 66 101 109 10.1016/j.gde.2020.12.010 33517184
    [Google Scholar]
  134. Carter A.B. Abruzzo L.V. Hirschhorn J.W. Electronic health records and genomics. J. Mol. Diagn. 2022 24 1 1 17 10.1016/j.jmoldx.2021.09.009 34656760
    [Google Scholar]
  135. Manolio T.A. Rowley R. Williams M.S. Opportunities, resources, and techniques for implementing genomics in clinical care. Lancet 2019 394 10197 511 520 10.1016/S0140‑6736(19)31140‑7 31395439
    [Google Scholar]
  136. Kho A.N. Rasmussen L.V. Connolly J.J. Practical challenges in integrating genomic data into the electronic health record. Genet. Med. 2013 15 10 772 778 10.1038/gim.2013.131 24071798
    [Google Scholar]
  137. Zhang J.Y. Commoning genomic solidarity to improve global health equality. Cell Genomics 2023 3 10 100405 10.1016/j.xgen.2023.100405 37868031
    [Google Scholar]
  138. Deyati A. Younesi E. Hofmann-Apitius M. Novac N. Challenges and opportunities for oncology biomarker discovery. Drug Discov. Today 2013 18 13-14 614 624 10.1016/j.drudis.2012.12.011 23280501
    [Google Scholar]
  139. Hird N. Ghosh S. Kitano H. Digital health revolution: Perfect storm or perfect opportunity for pharmaceutical R&D? Drug Discov. Today 2016 21 6 900 911 10.1016/j.drudis.2016.01.010 26821131
    [Google Scholar]
  140. Sahu S. Poplawska M. Lim S.H. Dutta D. CRISPR-based precision medicine for hematologic disorders: Advancements, challenges, and prospects. Life Sci. 2023 333 122165 10.1016/j.lfs.2023.122165 37832631
    [Google Scholar]
  141. Webster T.H. Wilson Sayres M.A. Genomic signatures of sex-biased demography: Progress and prospects. Curr. Opin. Genet. Dev. 2016 41 62 71 10.1016/j.gde.2016.08.002 27599147
    [Google Scholar]
  142. Wang C. Yuan X. Xue J. Targeted therapy for rare lung cancers: Status, challenges, and prospects. Mol. Ther. 2023 31 7 1960 1978 10.1016/j.ymthe.2023.05.007 37179456
    [Google Scholar]
  143. Hu W. Zheng Y. Xia P. Liang Z. The research progresses and future prospects of Tetrastigma hemsleyanum Diels et Gilg: A valuable Chinese herbal medicine. J. Ethnopharmacol. 2021 271 113836 10.1016/j.jep.2021.113836 33465440
    [Google Scholar]
  144. Chornenkyy Y. Yamamoto T. Hara H. Future prospects for the clinical transfusion of pig red blood cells. Blood Rev. 2023 61 101113 10.1016/j.blre.2023.101113 37474379
    [Google Scholar]
  145. Cano-Vicent A. Tambuwala M.M. Hassan S.S. Fused deposition modelling: Current status, methodology, applications and future prospects. Addit. Manuf. 2021 47 102378 10.1016/j.addma.2021.102378
    [Google Scholar]
  146. Liu Y. Yan Q. Zeng Z. Fan C. Xiong W. Advances and prospects of mRNA vaccines in cancer immunotherapy. Biochim. Biophys. Acta Rev. Cancer 2024 1879 2 189068 10.1016/j.bbcan.2023.189068 38171406
    [Google Scholar]
  147. Akade E. Aslani F. Verdi K. Bahadoram M. Kaydani G.A. Diagnosis of choroid plexus papilloma: Current perspectives and future directions. Cancer Pathog Ther 2023 2 3 173 179 10.1016/j.cpt.2023.09.005 39027146
    [Google Scholar]
  148. Liu Z. Han Y. Dang Q. Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint inhibitors: Current evidence and future directions. Int. Immunopharmacol. 2022 111 109173 10.1016/j.intimp.2022.109173 35998502
    [Google Scholar]
  149. Wallbillich N.J. Lu H. Role of c-Myc in lung cancer: Progress, challenges, and prospects. Chinese Med J Pul Crit Care Med 2023 1 3 129 138 10.1016/j.pccm.2023.07.001 37920609
    [Google Scholar]
  150. Routy B. Jackson T. Mählmann L. Melanoma and microbiota: Current understanding and future directions. Cancer Cell 2024 42 1 16 34 10.1016/j.ccell.2023.12.003 38157864
    [Google Scholar]
  151. Musyuni P. Bai J. Sheikh A. Precision medicine: Ray of hope in overcoming cancer multidrug resistance. Drug Resist. Updat. 2022 65 100889 10.1016/j.drup.2022.100889 36403342
    [Google Scholar]
  152. Li C. Zhu Z. Cheng L. Extraction, purification, characteristics, bioactivities, prospects, and toxicity of Lilium spp. polysaccharides. Int. J. Biol. Macromol. 2024 259 Pt 1 128532 10.1016/j.ijbiomac.2023.128532 38056732
    [Google Scholar]
  153. Hu X. Shou B. Yang L. Antimicrobial photodynamic therapy encapsulation technology: Frontier exploration and application prospects of novel antimicrobial technology. Chem. Eng. J. 2023 477 146773 10.1016/j.cej.2023.146773
    [Google Scholar]
  154. Cen X. Wang F. Huang X. Towards precision medicine: Omics approach for COVID-19. Biosafety Health 2023 5 2 78 88 10.1016/j.bsheal.2023.01.002 36687209
    [Google Scholar]
  155. Wang N. Gao M. Liu S. Electrochemical promotion of organic waste fermentation: Research advances and prospects. Environ. Res. 2024 244 117422 10.1016/j.envres.2023.117422 37866529
    [Google Scholar]
  156. Ratziu V. Hompesch M. Petitjean M. Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: Current status and future directions. J. Hepatol. 2024 80 2 335 351 10.1016/j.jhep.2023.10.015 37879461
    [Google Scholar]
/content/journals/cgt/10.2174/0115665232389198250711180547
Loading
Genomic Medicine: A Critical Review of its Impact on Diagnosing and Treating Genetic Disorders
Bentham Science Publishers ; https://doi.org/10.2174/0115665232389198250711180547
/content/journals/cgt/10.2174/0115665232389198250711180547
/content/journals/cgt/10.2174/0115665232389198250711180547
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: genetic disorder ; genetic sequencing technology ; diagnostic precision ; targeted therapy ; personalized treatment ; Genomic medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test